Cytokinetics cheers a PhIII readout for their heart drug developed with Amgen, but analysts and investors aren’t joining the party

Fifteen years after it entered the clinic, Amgen $AMGN and Cytokinetics’ closely watched heart drug popped out the other side, meeting the primary endpoint in a Phase III study. But it missed key secondary endpoints including reduction in cardiovascular death — and Cytokinetics CEO Robert Blum said whether they’ll approach…

Click to view original post